A COVID-19 vaccine developed by US-based Novavax elicited robust antibody responses and appeared to be safe in a Phase-I human trial, the company has said. No serious adverse events were reported and safety follow-up continues, Novavax said on Tuesday, while releasing the results of the study about its Covid-19 vaccine, NVX-CoV2373. The trial evaluated two doses of the vaccine across two dose levels -- 5 and 25 microgram -- in 131 healthy adults ages 18-59 years. NVX-CoV2373 is a vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes Covid-19 disease. Novavax has become the third US company to release Phase-1 data of Covid-19 vaccines after Moderna and Pfizer.

Source: dna August 05, 2020 10:33 UTC